In particular, LAG3 expression was frequently observed in aggressive tumor types, in carcinomas with lymphatic metastases and in TP53-mutated tumors, suggesting that LAG3 blockage could be of particular value for patients with an otherwise poor prognosis. This evidence concerns the gene LAG3 and neoplasm.